
    
      A randomized, double-blind, multicenter study to evaluate the safety and antiviral activity
      of the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with and
      without ribavirin (RBV) in treatment-na√Øve, noncirrhotic participants with chronic hepatitis
      C virus genotype 1b (HCV GT1b) infection.
    
  